PSTX / Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This more_horizontal

Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compa more_horizontal

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This more_horizontal

Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compa more_horizontal

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. more_horizontal

Poseida Therapeutics, Inc. granted Takeda its worldwide license to gene-therapy technologies that included piggyBac, Cas-Clover, and biodegradable DNA more_horizontal

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently o more_horizontal

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently o more_horizontal